SANTA CLARA, Calif., Jan. 6 /PRNewswire-FirstCall/ -- NewCardio, Inc., (OTC Bulletin Board: NWCI) a cardiac diagnostic technology provider, announced today that CEO, Dr. Branislav Vajdic, and CFO, Richard Brounstein, will present at the OneMedPlace Finance Forum 2010 at 2:45 p.m. (PT) on Tuesday, January 12, 2010 at The Sir Francis Drake Hotel in San Francisco, with a 40-minute breakout session to follow.
Company management will be available for one-on-one meetings on January 12th, 13th and 14th. Please contact Brett Maas at (646) 536-7331 or email@example.com to request a meeting.
Dr. Branislav Vajdic, commented, "NewCardio is poised for a breakthrough year as we have successfully launched QTinno(TM), our fully automated solution for cardiac safety and are making significant commercial progress as the industry accelerates its transition to automated solutions which provide higher quality results in a more timely and cost effective manner. In addition, we continue to solidify our 3-D platform technology, including our wireless focus through our CardioBip(TM) product, as evidenced by the encouraging clinical validation studies we recently announced. We look forward to the opportunity to present our vision to this investor audience."
About the OneMedForum 2010
Held annually in San Francisco, the OneMedPlace Finance Forum was created to connect emerging healthcare and life science companies with investors and strategic partners. Over 100 company presentations will occur by some of the most promising - and typically least recognized - companies in the world. Recognizing the impacts and opportunities connected to healthcare reform and the stimulus package, the conference has added a third day dedicated to Health Information. More information is available at http://www.onemedplace.com/onemedforum/index.php.
About NewCardio, Inc.
NewCardio is a cardiac diagnostic and services company developing and marketing proprietary software platform technologies to provide higher accuracy to, and increase the value of, the standard 12-lead electrocardiogram (ECG). NewCardio's three-dimensional ECG software platform reduces the time and expense involved in assessing cardiac status while increasing the ability to diagnose clinically significant conditions which were previously difficult to detect. NewCardio's software products and services significantly improve the diagnosis and monitoring of cardiovascular disease, as well as cardiac safety assessment of drugs under development. For more information, visit www.newcardio.com .
This press release contains forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based on currently available information and assumptions made by management. Although we believe that the assumptions on which the forward-looking statements contained herein are based are reasonable, any of those assumptions could prove to be inaccurate given the inherent uncertainties as to the occurrence or nonoccurrence of future events. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors, including the potential risks and uncertainties set forth in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2008 and relate to our business plan, our business strategy, development of our proprietary technology platform and our products, timing of such development, timing and results of clinical trials, level and timing of FDA regulatory clearance or review, market acceptance of our products, protection of our intellectual property, implementation of our strategic, operating and people initiatives, benefits to be derived from personnel and directors, ability to commercialize our products, our assumptions regarding cash flow from operations and cash on-hand, the amount and timing of operating costs and capital expenditures relating to the expansion of our business, operations and infrastructure, implementation of marketing programs, our key agreements and strategic alliances, our ability to obtain additional capital as, and when, needed, and on acceptable terms and general economic conditions specific to our industry, any of which could impact sales, costs and expenses and/or planned strategies and timing. We assume no obligation to, and do not currently intend to, update these forward-looking statements.
To join our email distribution please click this link: http://www.b2i.us/irpass.asp?BzID=1645&to=ea&s=0
Investor Contact: Hayden IR Jeff Stanlis, VP of Communications (602) 476-1821 firstname.lastname@example.org
SOURCE NewCardio, Inc.